Albumin Infusion in Severe Hyperbilirubinemia: Binding Capacity & Clinical Protocol

Albumin and Bilirubin: Understanding the Binding Relationship

Albumin is the primary transport protein for unconjugated bilirubin in the neonatal circulation. Each molecule of albumin binds one molecule of unconjugated bilirubin at a high-affinity primary binding site, with additional low-affinity binding sites capable of carrying more bilirubin under physiological conditions. This binding relationship is central to neonatal jaundice pathophysiology because only unbound (free) bilirubin can cross the blood-brain barrier and cause kernicterus.

In severe hyperbilirubinemia, when the bilirubin load exceeds albumin-binding capacity, free bilirubin levels rise dramatically, creating the neurotoxic risk that makes exchange transfusion necessary. Albumin infusion in this context serves as a pharmacological strategy to increase bilirubin-binding capacity, reduce free bilirubin, and enhance the efficiency of both phototherapy and exchange transfusion in Indian NICU settings.

Bilirubin-Albumin Binding Physiology

Binding Capacity and Affinity

Normal neonatal serum albumin ranges from 2.5-3.5 g/dL. Each gram of albumin can bind approximately 8.5 mg of unconjugated bilirubin at the primary high-affinity site. For a neonate with albumin of 3.0 g/dL, the theoretical maximum binding capacity is approximately 25.5 mg/dL of bilirubin. However, several factors reduce effective binding capacity in clinical practice:

• Acidosis (pH less than 7.2): Reduces albumin-bilirubin binding affinity by up to 50%
• Hypothermia: Decreases binding affinity
• Competing drugs: Sulfonamides, ceftriaxone, furosemide, and ibuprofen displace bilirubin from albumin binding sites
• Free fatty acids: Elevated in stressed, septic, or hypothermic neonates; compete for albumin binding
• Gestational age: Preterm infants have lower albumin levels and reduced binding affinity compared to term neonates

The Concept of Free Bilirubin

Free (unbound) bilirubin is the fraction not bound to albumin. It is lipid-soluble and can cross the blood-brain barrier to cause acute bilirubin encephalopathy (ABE) and kernicterus. While total serum bilirubin (TSB) is the standard clinical measurement, free bilirubin correlates more closely with neurotoxicity risk. The bilirubin-to-albumin ratio (B/A ratio) serves as a practical surrogate for free bilirubin estimation.

Clinical Indications for Albumin Infusion

Pre-Exchange Transfusion Priming

The most established indication for albumin infusion is as a pre-exchange transfusion adjunct. By infusing albumin 1-2 hours before exchange transfusion, bilirubin is drawn from extravascular tissue compartments (including potentially the brain) into the intravascular space where it binds to the infused albumin. During the subsequent exchange, this intravascular bilirubin-albumin complex is removed, resulting in 30-40% greater bilirubin clearance compared to exchange without pre-albumin infusion.

Hypoalbuminemia with Severe Jaundice

Neonates with serum albumin less than 2.5 g/dL are at increased risk for bilirubin neurotoxicity at lower TSB levels. This is common in:

• Preterm infants (especially less than 32 weeks)
• Neonates with sepsis
• Small for gestational age (SGA) babies
• Infants with hepatic dysfunction
• Neonates on prolonged parenteral nutrition

In these cases, albumin infusion restores binding capacity and provides a margin of safety while definitive treatment (phototherapy or exchange) is underway.

NNF India Position

The NNF guidelines state that albumin infusion is an optional but potentially beneficial adjunct in the following situations:

1. Serum albumin less than 3 g/dL with TSB approaching exchange levels
2. Pre-exchange transfusion to enhance bilirubin removal efficiency
3. B/A ratio exceeding critical thresholds (greater than 8.0 mg/g for term, greater than 7.2 for 35-37 weeks, greater than 6.8 for less than 35 weeks)

Dosing and Administration Protocol

Parameter	Recommendation	Notes
Preparation	20% human albumin	5% can be used but larger volume needed
Dose	1 g/kg (= 5 mL/kg of 20%)	Single dose; may repeat if albumin remains low
Infusion rate	Over 1-2 hours	Start at 1 mL/kg/hr; increase if tolerated
Timing (pre-exchange)	1-2 hours before exchange	Allows equilibration between compartments
Monitoring	Heart rate, BP, SpO2	Watch for fluid overload signs

Administration Steps

1. Confirm serum albumin level and TSB; calculate B/A ratio
2. Ensure intensive phototherapy is running—HEAMAC LED phototherapy units provide optimal irradiance during the pre-exchange preparation period
3. Prepare 20% human albumin: 1 g/kg = 5 mL/kg
4. Infuse through peripheral or central IV line over 1-2 hours
5. Monitor vital signs every 15 minutes during infusion; watch for signs of fluid overload (tachycardia, hepatomegaly, respiratory distress)
6. Recheck TSB 1 hour after albumin infusion (expect a transient TSB rise as bilirubin is pulled into the intravascular compartment)
7. Proceed with exchange transfusion within 1-2 hours of completing albumin infusion

Evidence Base

Efficacy of Pre-Exchange Albumin

A systematic review of 5 controlled trials showed that pre-exchange albumin infusion increased bilirubin removal during double-volume exchange transfusion by approximately 33% (mean difference 2.8 mg/dL) compared to exchange without albumin. The post-exchange TSB nadir was lower, and the rebound rate in the first 6 hours was also reduced.

Indian Clinical Experience

Studies from multiple Indian tertiary centers have confirmed the benefit of pre-exchange albumin in the Indian context. A study from Safdarjung Hospital, New Delhi showed that pre-exchange albumin reduced post-exchange bilirubin rebound from 35% to 18% of cases requiring repeat exchange. The cost-benefit analysis is favorable: one vial of 20% albumin (100 mL, approximately INR 800-1,500) can prevent the need for repeat exchange transfusion (cost INR 15,000-35,000) in a significant proportion of cases.

Albumin for Enhancing Phototherapy

Some clinicians use albumin infusion to enhance phototherapy efficacy in hypoalbuminemic neonates. The rationale is that albumin-bound bilirubin is maintained in the intravascular space where it is more accessible to phototherapy light. While this approach is physiologically sound, clinical trial evidence is limited. A small Indian RCT from PGI Chandigarh showed that albumin supplementation in preterm neonates with albumin less than 2.5 g/dL reduced the duration of phototherapy by approximately 14 hours, but larger trials are needed.

Safety Considerations

Volume Overload Risk

Albumin 20% is a colloid that draws fluid from the extravascular to intravascular space, expanding plasma volume by approximately 3-4 times the infused volume. In neonates with compromised cardiac function, patent ductus arteriosus (PDA), or those receiving other IV fluids, this can precipitate congestive heart failure and pulmonary edema. Careful fluid balance assessment before infusion is essential.

Contraindications and Cautions

• Congestive heart failure: Relative contraindication—use with extreme caution
• Severe anemia (Hb less than 8 g/dL): Albumin may worsen cardiac output; correct anemia first
• Renal failure: Impaired fluid handling increases overload risk
• Known allergy to human albumin: Extremely rare but possible

Drug Interactions

Albumin infusion can affect the pharmacokinetics of other protein-bound drugs. When administering albumin to a neonate receiving multiple medications, be aware that increased albumin may bind drugs such as phenobarbital and phenytoin, potentially reducing their free fraction and clinical effect. Conversely, drugs like ceftriaxone and sulfonamides can displace bilirubin from albumin, counteracting the benefit of albumin infusion.

Practical Recommendations for Indian NICUs

Government Hospitals

Human albumin 20% is not always available in government hospital pharmacies due to cost constraints. Where available, it should be prioritized for neonates with confirmed hypoalbuminemia (less than 2.5 g/dL) who are approaching exchange transfusion thresholds. Serum albumin measurement should be included in the standard workup for all neonates with significant jaundice.

Private NICUs

In private practice, albumin infusion can be offered as part of comprehensive jaundice management. Transparent counselling about its role (adjunctive, not curative) and expected benefits helps manage parental expectations. Cost (approximately INR 800-1,500 per vial) is modest relative to overall NICU expenses.

Integration with Phototherapy Strategy

Albumin infusion should always be combined with intensive phototherapy for maximum benefit. High-irradiance LED phototherapy devices, available through HEAMAC phototherapy rental services, provide the optimal irradiance levels needed to convert bilirubin into photo-isomers while albumin ensures the bilirubin remains in the intravascular compartment where phototherapy is most effective.

Key Takeaway: Albumin infusion is a safe and effective adjunct in severe neonatal hyperbilirubinemia. Its primary role is pre-exchange transfusion to enhance bilirubin removal, with secondary utility in hypoalbuminemic neonates receiving intensive phototherapy. It should not delay definitive treatment—when exchange transfusion criteria are met, proceed without unnecessary delay.

Summary of Albumin Use in Neonatal Jaundice

Clinical Scenario	Albumin Indicated?	Dose	Evidence Level
Pre-exchange transfusion	Yes (recommended)	1 g/kg IV over 1-2 hrs	Moderate (multiple RCTs)
Hypoalbuminemia + high TSB	Yes	1 g/kg IV over 1-2 hrs	Low-moderate
Enhancing phototherapy in preterm	Consider	1 g/kg IV over 1-2 hrs	Low (limited trials)
Routine jaundice, normal albumin	No	N/A	Not recommended